Targeting NLRP3 in Myelodysplastic Syndrome: Initial Results from Phase Ib Trial of DFV890
Time: 9:00 am
day: Conference Day One AM
Details:
- Demonstrating NLRP3 pathway engagement through decreased systemic inflammatory cytokines and biomarker activity
- Evaluating the therapeutic potential of NLRP3 inhibition in earlier-stage MDS patients to enhance clinical response
- Investigating the link between inflammatory signaling and CHIP-associated mutations
